In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug ; volume:8 ; number:1 ; day:2 ; month:5 ; year:2018 ; pages:1-12 ; date:12.2018
Scientific reports ; 8, Heft 1 (2.5.2018), 1-12, 12.2018
- Urheber
-
Xu, Yanan
- Beteiligte Personen und Organisationen
-
Zhu, Xiaoyin
Wang, Hongbo
Sun, Shanyue
Yue, Xin
Tian, Jingwei
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-25036-0
- URN
-
urn:nbn:de:101:1-2018063021362916108716
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Xu, Yanan
- Zhu, Xiaoyin
- Wang, Hongbo
- Sun, Shanyue
- Yue, Xin
- Tian, Jingwei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Environmentally-relevant concentrations of the antipsychotic drugs sulpiride and clozapine induce abnormal dopamine and serotonin signaling in zebrafish brain
Interaction of Platelets with Serotonin and Dopamine
Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Environmentally-relevant concentrations of the antipsychotic drugs sulpiride and clozapine induce abnormal dopamine and serotonin signaling in zebrafish brain
Interaction of Platelets with Serotonin and Dopamine
Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications
Synthesis and biological investigations of 3β-aminotropane arylamide derivatives with atypical antipsychotic profile
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Environmentally-relevant concentrations of the antipsychotic drugs sulpiride and clozapine induce abnormal dopamine and serotonin signaling in zebrafish brain
Interaction of Platelets with Serotonin and Dopamine
Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
Atypical antipsychotic agents; Peas in a pod or chalk and cheese?
Unlocking treatment success: predicting atypical antipsychotic continuation in youth with mania
2-Bromoterguride–a potential atypical antipsychotic drug without metabolic effects in rats
Gender differences in the use of atypical antipsychotic medications for ICU delirium
Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone
Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone
Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications